MedTrace Logo

Impact of Novel Thoracic Wall Blocks With Dexmetomidine on Inflammatory Markers Following Breast Cancer Surgery

NCT04860115 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2021-09-28

No results posted yet for this study

Summary

The study will test the hypothesis that inflammatory markers measured at 24 hours after breast cancer surgery will be lower in patients receiving PECS II and PIFB blocks, supplemented with dexmetomidine compared to standard care group.

Conditions

  • Inflammatory Markers

Interventions

PROCEDURE

Modified pectoralis block (PEC II) and pecto-intercostal fascial plane block (PIFB)

PECS II: Ultrasound guided block involving injection of 20 ml of 0.25% L-bupivacaine with dexmetomidine into an interfascial plane between the serratus anterior muscle and the external intercostal muscles followed by the needle withdrawal into an interfascial plane between the pectoralis major and pectoralis minor muscle where further 10ml will be administered. PIFB: Ultrasound guided block involving injection of 10 ml of 0.25% L-bupivacaine with dexmetomidine into an iterfascial plane between the pectoralis major and the intercostal muscles approximately 2 cm laterally from the sternum to cover T2 to T6 dermatomes.

Sponsors & Collaborators

  • F.D. Roosevelt Teaching Hospital with Policlinic Banska Bystrica

    collaborator OTHER

  • Louis Pasteur University Hospital Kosice

    collaborator UNKNOWN

  • St. Elizabeth Cancer Institute, Slovakia

    lead OTHER

Principal Investigators

  • Tomas Hitka, MD · St. Elizabeth Cancer Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-01
Primary Completion
2023-11-01
Completion
2023-12-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04860115 on ClinicalTrials.gov